NCT00485758View on ClinicalTrials.gov

Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)

PHASE3CompletedINTERVENTIONAL
Enrollment

796

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

ER niacin/laropiprant

One tablet of ER niacin/laropiprant (1g); advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study 36 Weeks.

DRUG

Comparator : placebo (unspecified)

ER niacin/laropiprant Placebo

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00485758 - Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069) | Biotech Hunter | Biotech Hunter